Company intelligence / Profile preview

Blue Eyes Biotech

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Blue Eyes Biotech is a pre-clinical stage biotechnology company focused on developing innovative therapies for ophthalmic diseases. The company's primary research centers on multi-target tyrosine kinase inhibitors designed to treat retinal vascular disorders such as neovascular age-related macular degeneration and diabetic macular edema. By targeting key pathways including VEGF, PDGF, and FGF, Blue Eyes Biotech aims to provide more durable and effective treatment options compared to current standard-of-care biologics. The company is currently advancing its lead candidates through optimization and early safety studies to support future clinical development.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Blue Eyes Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Eyes Biotech.

Explore the full profile